沃森生物：四价流脑结合疫苗目前处于III期临床研究阶段

Core Viewpoint - Watson Bio (300142) is currently in the III phase of clinical research for its quadrivalent meningococcal vaccine, adhering strictly to national drug registration procedures and regulations [1] Group 1 - The company is actively engaged in the development of a quadrivalent meningococcal vaccine [1] - The vaccine is in the III phase of clinical trials, indicating advanced stages of development [1] - The company emphasizes compliance with national drug registration procedures and requirements [1]